Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
Open Access
- 2 January 2023
- journal article
- other
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (1) , 2168947
Abstract
Dear Editor, We would like to reply to “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11years: Correspondence” regarding our article entitled “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5–11years: Results from an active pharmacovigilance study in central Italy.”Keywords
Funding Information
- No funding
This publication has 5 references indexed in Scilit:
- Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Results from an active pharmacovigilance study in central ItalyHuman Vaccines & Immunotherapeutics, 2022
- Public health, personalized medicine, and COVID-19 in the pre-vaccination phase: a narrative review of the literature on unfavorable prognostic factors in Italian patients2022
- Will Host Genetics Affect the Response to SARS-CoV-2 Vaccines? Historical PrecedentsFrontiers in Medicine, 2022
- Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional StudyJournal of Community Health, 2021
- Precision Medicine and Public Health: New Challenges for Effective and Sustainable HealthJournal of Personalized Medicine, 2021